Table 1.
Clinical Characteristics in Patients With or Without Major Adverse Cardiac Events
| Variable | Overall (n = 1,596) | MACE | P Value | |
|---|---|---|---|---|
| No (n = 1384) | Yes (n = 212) | |||
| Demographics | ||||
| Age (y) | 64.5 ± 11.9 | 63.3 ± 11.5 | 72.3 ± 10.9 | <0.001 |
| Male | 1070 (67.0%) | 950 (68.6%) | 120 (56.6%) | 0.001 |
| Body mass index (kg/m2) | 23.7 ± 3.06 | 23.8 ± 3.05 | 22.6 ± 2.91 | <0.001 |
| Initial presentation | ||||
| Systolic blood pressure (mmHg) | 136.5 ± 29.8 | 137.3 ± 28.4 | 131.2 ± 37.1 | 0.043 |
| Heart rate (beats/min) | 79.6 ± 20.1 | 78.2 ± 19.0 | 89.1 ± 24.3 | <0.001 |
| ST‐elevation myocardial infarction | 688 (43.4%) | 608 (44.1%) | 80 (38.6%) | 0.141 |
| Killip class >1 | 408 (25.6%) | 279 (20.2%) | 129 (61.1%) | <0.001 |
| Past history | ||||
| Previous coronary heart disease | 295 (18.7%) | 236 (17.3%) | 59 (28.5%) | <0.001 |
| Hypertension | 725 (45.9%) | 613 (44.6%) | 112 (54.4%) | 0.009 |
| Diabetes mellitus | 454 (28.8%) | 374 (27.3%) | 80 (38.6%) | 0.001 |
| Hyperlipidemia | 416 (28.9%) | 391 (31.1%) | 25 (13.7%) | <0.001 |
| Current smoking | 651 (43.1%) | 578 (43.9%) | 73 (37.6%) | 0.099 |
| Left ventricular ejection fraction (%) | 51.2 ± 11.2 | 52.2 ± 10.6 | 42.5 ± 12.7 | <0.001 |
| Laboratory findings | ||||
| Hemoglobin (g/dL) | 13.3 ± 2.10 | 13.5 ± 1.96 | 11.9 ± 2.40 | <0.001 |
| Red cell distribution width (%) | 13.3 ± 1.24 | 13.3 ± 1.22 | 13.8 ± 1.27 | <0.001 |
| Serum creatinine (mg/dL) | 1.17 ± 1.16 | 1.06 ± 0.98 | 1.85 ± 1.82 | <0.001 |
| Peak creatine‐kinase MB (ng/mL) | 63.8 ± 157.0 | 61.2 ± 149.3 | 81.3 ± 201.6 | 0.172 |
| Peak cardiac troponin I (ng/mL) | 48.5 ± 91.3 | 47.0 ± 83.5 | 58.8 ± 132.4 | 0.219 |
| Total cholesterol (mg/dL) | 179.2 ± 42.5 | 180.4 ± 41.7 | 169.9 ± 47.8 | 0.002 |
| Triglycerides (mg/dL) | 142.6 ± 120.6 | 145.5 ± 125.9 | 119.6 ± 61.1 | <0.001 |
| High‐density lipoprotein cholesterol (mg/dL) | 44.4 ± 12.5 | 44.6 ± 12.4 | 43.1 ± 12.9 | 0.147 |
| Low‐density lipoprotein cholesterol (mg/dL) | 118.5 ± 38.9 | 119.4 ± 38.1 | 111.5 ± 43.9 | 0.026 |
| Percutaneous coronary intervention at index hospitalization | 1,201 (75.7%) | 1117 (80.9%) | 84 (40.6%) | <0.001 |
| Discharge medication | ||||
| Antiplatelet agents | 1510 (94.6%) | 1335 (96.5%) | 175 (82.5%) | <0.001 |
| β‐blockers | 1349 (84.5%) | 1207 (87.2%) | 142 (67.0%) | <0.001 |
| ACE‐I/ARBs | 1356 (85.0%) | 1216 (87.9%) | 140 (66.0%) | <0.001 |
| Lipid‐lowering drugs | 1126 (70.6%) | 999 (72.2%) | 127 (59.9%) | <0.001 |
Abbreviations: ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; MACE, major adverse cardiac event.
Data are mean ± standard deviation for continuous variables and percentages for categorical variables.